May 29 was a good day for Lifland, the national appellate coordinating counsel for Merck. In that one day, he received news from New Jersey and Texas that he had won multimillion-dollar reversals for Merck in the Vioxx mass tort litigation that was ongoing in both states. The daily double was a highlight in a strong year in which Lifland achieved reversals amounting to $5 billion in compensatory and punitive damages. He persuaded the U.S. Supreme Court in June to reduce the award stemming ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In